Multiple Myeloma | Clinical


ODAC Votes Against Melphalan Flufenamide in R/R Multiple Myeloma

September 22, 2022

Due to the potential detriment in overall survival, its failure to demonstrate a progression-free survival benefit, and the lack of a known appropriate dose, ODAC has voted that melphalan flufenamide is not favorable in relapsed/refractory multiple myeloma.

Dara-KRd Leads to Encouraging Responses in Newly Diagnosed Multiple Myeloma

September 08, 2022

The phase 2 MASTER trial of daratumumab, carfilzomib, lenalidomide, and dexamethasone demonstrates the promise of minimal residual disease surveillance in newly diagnosed multiple myeloma with 0 or 1 high-risk cytogenetic abnormalities

Dara-RVd Reduces Risk of Progression or Death in Transplant-Eligible NDMM

August 28, 2022

The combination of daratumumab plus lenalidomide, bortezomib, and dexamethasone continued to show superior efficacy in patients with newly diagnosed multiple myeloma based on the GRIFFIN trial's final analysis reported at the 19th International Myeloma Society annual meeting.